MAXCYTE INC. - COMMON

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

08 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

03 янв 2024 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

02 янв 2024 01:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

11 дек 2023 15:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

16 ноя 2023 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

08 ноя 2023 15:05:01 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

06 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

04 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

06 сен 2023 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

05 сен 2023 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

09 авг 2023 15:05:01 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

01 авг 2023 07:05:51 Источник Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

13 июл 2023 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

10 июл 2023 07:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

06 июл 2023 07:05:05 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

01 июн 2023 15:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

10 май 2023 15:05:01 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 май 2023 07:05:53 Источник Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

12 апр 2023 15:05:30 Источник Nasdaq GlobeNewswire

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

27 мар 2023 15:05:00 Источник Nasdaq GlobeNewswire